Search Results
Your search for ,NOt matches 22378 pages
Showing 9901 - 9950Phase III PROfound Study Evaluates Olaparib in Setting of Metastatic, Castration-Resistant Prostate Cancer
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib delayed disease progression and appears to improve survival, compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair (HRR) genetic...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
Immunotherapy Shows Strong Benefit in Two Gynecologic Cancers
In studies reported at the ESMO Congress 2019, immunotherapy yielded encouraging outcomes in two gynecologic cancer populations in need of new treatments, including patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer. ...
Selinexor Plus Dexamethasone Studied in Triple-Class Refractory Multiple Myeloma
In a phase IIb study (STORM Part 2) reported in The New England Journal of Medicine, Ajai Chari, MD, of Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and colleagues found that oral selinexor and dexamethasone were active in some patients with multiple myeloma refractory to prior...
Rates of Non–Guideline-Concordant Lung Cancer Treatment in the United States
Only about 6 in 10 patients with lung cancer in the United States receive the minimal lung cancer treatments recommended by National Comprehensive Cancer Network® (NCCN) Guidelines, according to new research published by Blom et al in the Annals of the American Thoracic Society. Erik F. Blom, MD,...
Exercise Intolerance in Adult Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Ness et al found a high rate of exercise intolerance among adult survivors of childhood cancer, irrespective of exposure to cardiotoxic treatment. Exercise intolerance was associated with poorer overall survival. The study involved 1,041...
Expert Point of View: Sanjay Popat, FRCP, PhD
Formal discussant of the CheckMate 227 trial, Sanjay Popat, FRCP, PhD, of the Royal Marsden Hospital, London, had some reservations about endorsing nivolumab/ipilimumab as a new standard of care, mainly related to toxicity. “The landscape of treating advanced non–small cell lung cancer has changed ...
CheckMate 227: Nivolumab Plus Ipilimumab Presents Another Option in First-Line Treatment of Advanced Non–Small Cell Lung Cancer
The combination of nivolumab and ipilimumab improved overall survival compared with chemotherapy as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) expression of at least 1%, according to the results of CheckMate 227....
Osimertinib Improves Overall Survival vs Gefitinib, Erlotinib in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: FLAURA Phase III Trial
The third-generation tyrosine kinase inhibitor osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the ...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
Checkpoint Inhibitors Benefit Women With Advanced Stages of Cervical, Endometrial Cancers
Immunotherapy studies reported at the ESMO Congress 2019 yielded encouraging outcomes in patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer. The combination of nivolumab and ipilimumab, with two different dosing...
Phase III Trials Suggest Paradigm Shift With PARP Inhibitors in Ovarian Cancer
At the ESMO Congress 2019, ovarian cancer was a topic of heightened interest, particularly due to findings reported in several important phase III studies of PARP inhibitors in front-line maintenance therapy for patients with newly diagnosed advanced disease—and not just those with BRCA mutations....
Neoadjuvant Immunotherapy Plus Chemotherapy Active in Women With Early Triple-Negative Breast Cancer
Immunotherapy has changed the treatment paradigms for melanoma, lung cancer, bladder cancer, and renal cancer. Now, checkpoint inhibitor therapy is making inroads in triple-negative breast cancer—one of the most difficult-to-treat aggressive types of breast cancer. Late-breaking results of the...
MONALEESA-3, MONARCH 2: CDK4/6 Inhibitors Plus Fulvestrant Benefit Survival in Advanced Breast Cancer
CDK4/6 inhibitors improve overall survival in advanced breast cancer, according to results of two important phase III trials reported at the ESMO Congress 2019. Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles Women’s Cancer Research Program, presented the findings from the...
ESMO Congress 2019 Offers a Global Stage for Important Clinical Data
The European Society for Medical Oncology (ESMO) Congress 2019, held September 27 to October 1 in Barcelona, welcomed clinicians, researchers, journalists, and exhibitors from around the world to hear advances across the oncology spectrum, in both clinical medicine and basic research. For this...
Financial Burdens of Patients With Cirrhosis and Impact on Screening for HCC
Data from a new study presented by Singal et al at The Liver Meeting found that patients with cirrhosis in the United States have substantial financial burden and this is associated with underuse of surveillance for hepatocellular carcinoma (HCC) (Abstract 201). Improved intervention strategies are ...
Short-Term Survival in Patients Aged 85 Years and Older After Colorectal Cancer Surgery
Results from a preliminary research study showed the majority of patients aged 85 years and older were still alive in the short-term after undergoing segmental colectomy for stage II and III colon cancer. Kaur et al presented these findings at the American College of Surgeons Clinical Congress...
Head and Neck Melanoma in Adolescents and Young Adults: 1995 to 2014
Head and neck melanoma appears to be on the rise in young people in the United States and Canada, according to a study by Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES, of the Saint Louis University (SLU) School of Medicine, and colleagues. Because the prognosis of head and neck melanoma is...
Your Stories: Behind the Breakthroughs
On a Saturday morning, a wife wakes to telling signs that her husband is not well. Before Sunday, a devasting diagnosis comes that a young father has a 1% chance of surviving. The search is on for a life-extending treatment. Erin Miller, who lost her husband, Mike, and Erin’s sister, Dana...
New JCO CCI Article Discusses Difficulties in Gathering Real-World Evidence
A new JCO Clinical Cancer Informatics (JCO CCI) article highlights the challenges in—and need for—obtaining real-world evidence for assessing the effectiveness of precision medicine on areas such as survival, quality of life, cost, and health disparities. The paper, titled “Clinical Molecular...
Cancer.Net: Physician-Generated Content for Patients With Cancer Worldwide
Receiving a cancer diagnosis is a disorienting moment for our patients who are then faced with making difficult decisions regarding their treatment. In order to improve shared decision-making and to increase patient involvement in their care, it is essential to provide patients and their families...
Expert Point of View: Ana Oaknin, MD, PhD
Ana Oaknin, MD, PhD, Head of the Gynecologic Cancer Program at Vall d’Hebron Institute of Oncology, Barcelona, discussed the PRIMA/ENGOT-OV26/GOG-3012 trial along with the results of the phase III PAOLA-1/ENGOT-ov25 trial of olaparib plus bevacizumab maintenance. According to Dr. Oaknin, the...
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets
In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the PARP inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a homologous recombination...
How Clonal Hematopoiesis of Indeterminate Potential Increases the Risk of Heart Disease and Blood Cancers as People Age
Although stem cells throughout the body acquire genetic mutations over time, usually these alterations do not affect how the stem cells function or cause disease. However, recent research in clonal hematopoiesis and aging has found an association between clonal expansion of hematopoietic cells with ...
Fedratinib: Back From Development Limbo for the Treatment of Myeloproliferative Neoplasms
In September 2019, Dr. Claire Harrison and colleagues, myself among them, presented two new analyses regarding the use of the JAK2 and FLT3 inhibitor fedratinib in myelofibrosis at the Society of Hematologic Oncology (SOHO) Annual Meeting, with resulting publication in Clinical Lymphoma, Myeloma...
Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
On May 15, 2019, venetoclax was approved for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 Supporting Efficacy Data Approval was based on findings from the open-label phase III CLL14 trial (ClinicalTrials.gov...
Early Lung Cancer Detection Followed by Minimally Invasive Surgery Saves Lives
Lung cancer remains the number one cancer killer, leading to about 150,000 deaths per year in the United States and accounting for approximately 25% of all cancer deaths in the nation. Early detection has improved survival in other malignancies such as breast, colon, and cervical cancers, but...
Management of Locally Advanced Pancreatic Cancer: A Call for Action
Advances in systemic therapy and supportive care, as well as ongoing improvements in surgical techniques, have led to improved survival for many patients with pancreatic ductal adenocarcinoma. We have observed increased survival with FOLFIRINOX (leucovorin, fluorouracil, irinotecan,...
The Oncology Care Model and Quality of Care: Defining, Measuring, and Implementing New Approaches to Cancer Care
The Oncology Care Model was instituted in 2016 by the Center for Medicare & Medicaid Innovation as a move away from the fee-for-service payment model and toward value-based care. It has sparked discussion ever since. How should quality be defined? Whose and what values should it reflect? How...
Third-Line Cabazitaxel Improves Outcomes in Patients With Metastatic Prostate Cancer
Third-line treatment with cabazitaxel extended progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer in the CARD trial. These results provide the first evidence from a randomized phase III trial for a survival benefit with third-line therapy, and ...
Apalutamide Treatment for Metastatic Castration-Sensitive Prostate Cancer and Health-Related Quality of Life
In an analysis of the phase III TITAN trial reported in The Lancet Oncology, Neeraj Agarwal, MD, and colleagues found that that treatment with apalatuamide was associated with preserved health-related quality of life, including pain and fatigue outcomes, in patients with metastatic...
Acute Toxicity With Intensity-Modulated Fractionated Radiotherapy vs Stereotactic Body Radiotherapy for Prostate Cancer
In an analysis from the phase III PACE-B trial reported in The Lancet Oncology, Nicholas van As, MD, and colleagues found that shortened treatment courses with stereotactic body radiotherapy did not increase gastrointestinal or genitourinary acute toxicity vs intensity-modulated fractionated...
Remembering Craig Alguire
It is with great sadness that we report Craig Alguire, MD, 42, died on October 11, 2019, at his home in Grand Rapids, Michigan. Diagnosed with grade 4 glioblastoma multiforme in 2015, Dr. Alguire chronicled the effects the cancer was having on his life in his Patient’s Corner column, published in...
FDA Awards Research Grants for the Study of Rare Cancers
The U.S. Food and Drug Administration (FDA) recently awarded 12 new clinical trial research grants totaling more than $15 million over the next 4 years, many of them focusing on cancer. Also, the FDA awarded two new research grants for natural history studies in rare diseases, totaling more than...
Expert Point of View: Mansoor R. Mirza, MD
The time has come to offer all patients a PARP [poly (ADP-ribose) polymerase] inhibitor,” said Mansoor R. Mirza, MD, Chief Oncologist at Copenhagen University Hospital and the invited discussant of the VELIA trial at the ESMO Presidential Symposium. He noted, however, that he wasn’t sure veliparib...
Veliparib Plus Chemotherapy Meets Primary Endpoint in Advanced Ovarian Cancer
As first-line treatment for women with advanced ovarian cancer, the addition of veliparib during induction followed by veliparib maintenance therapy significantly reduced the risk of disease progression or death in the phase III VELIA/GOG-3005 trial reported at the European Society for Medical...
2019 NCRI: Higher IGF-1 and Free Testosterone Levels May be Risk Factors for Prostate Cancer
Men with higher levels of free (biologically active) testosterone and insulin-like growth factor-1 (IGF-1) in their blood are more likely to be diagnosed with prostate cancer, according to research presented by Travis et al at the 2019 National Cancer Research Institute (NCRI) Cancer Conference....
2019 NCRI: CA125 Testing May Help General Practitioners to Detect Ovarian Cancer
Testing for levels of the serum biomarker cancer antigen 125 (CA125) in the blood may be a useful tool for the detection of ovarian cancer, and could help detect other types of cancer among patients in primary care, according to research presented by Funston et al at the 2019 National Cancer...
2019 NCRI: Hepatocellular Carcinoma Incidence and Mortality Rates in England Have Tripled Over the Past 20 Years
From 1997 to 2016, incidence and deaths from hepatocellular carcinoma have tripled in England, according to research presented by Burton et al at the 2019 National Cancer Research Institute (NCRI) Cancer Conference. Anya Burton, PhD, a cancer epidemiologist at Public Health England, said in a press ...
2019 NCRI: Use of Mendelian Randomization to Determine Role of Human Gut Microbiome in Colorectal Cancer Development
A study using a technique called Mendelian randomization to investigate the causal role played by bacteria in the development of colorectal cancer was presented at the 2019 National Cancer Research Institute (NCRI) Cancer Conference. First study author Kaitlin Wade, PhD, of the University of...
How Patients Add Life to Their Days
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Daratumumab Combination Therapy for Patients With Multiple Myeloma Who Are Eligible for Transplantation
On September 26, 2019, daratumu-mab (Darzalex) was approved in combination with bortezomib, thalidomide, and dexamethasone for the treatment of multiple myeloma in newly diagnosed adult patients eligible for autologous stem cell transplantation (ASCT).1,2 Supporting Efficacy Data Approval was based ...
Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals
In a study reported in JAMA Oncology,1Jonathan M. Loree, MD, of BC Cancer, Vancouver, British Columbia, Canada, and colleagues found that race and race subgroup analyses were frequently not included in reported trials supporting U.S. Food and Drug Administration (FDA) oncology drug approvals...
The Role of Oncologists in Helping Cancer Survivors to Quit Smoking
Several oncology organizations have created guidelines for oncology specialists to help patients with cancer to quit smoking. ASCO has far-reaching goals aimed at tobacco reduction, including cessation tools and other resources. To shed light on the current work in this area, The ASCO Post spoke...
Immunotherapy Combinations Redefine Outcomes for Patients With Advanced Renal Cell Carcinoma
The treatment landscape for patients with advanced renal cell carcinoma has changed drastically over the past several years with the introduction of many new therapeutic options for patients. The revolution began with the U.S. Food and Drug Administration (FDA) approval of nivolumab and ipilimumab...
CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
As reported in The Lancet Oncology by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, extended follow-up of the phase III CheckMate 214 trial has shown maintained survival benefit of first-line nivolumab/ipilimumab vs sunitinib among patients with...
Personalized Treatment Approaches on the Horizon for Myelodysplastic Syndromes
Despite the spate of recent drug approvals in blood cancer, it’s been more than 13 years since the U.S. Food and Drug Administration (FDA) has approved a treatment for myelodysplastic syndromes (MDS), a bone marrow disorder characterized by ineffective hematopoiesis. Nevertheless, data from a...
Abemaciclib Benefits Patients With HER2-Positive Breast Cancer in monarcHER Trial
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are associated with a robust benefit in patients with hormone receptor–positive, HER2-negative breast cancer, but now the monarcHER trial has confirmed their benefit in the HER2-positive population. The new findings were reported at the...
Nearly One-Quarter of Completed Lung Cancer Clinical Trials Remain Unpublished
A new analysis has found that the results of up to one-fourth of completed lung cancer clinical trials are not published. This finding was published in a research letter by Al-Shbool et al in JAMA Network Open. “It is surprising to see that a quarter of trials that have been completed end up not...
Studies Report Efficacy of Proton Radiotherapy for Hepatocellular Carcinoma
Two new studies published in the International Journal of Radiation Oncology • Biology • Physics focused on the use of proton radiation therapy to treat patients with hepatocellular carcinoma. The first study, by Sanford et al, found that proton radiation may extend overall survival compared to...
